Berg Health, a pharmaceutical startup, has developed a cancer drug in half the time expected by using a specialised form of artificial intelligence which takes samples from patients with the most aggressive strains of cancer and compares﻿ them to non-cancerous patients. The company is working on an AI system that can analyse data collected during clinical trials for drugs or vaccines against cancer. Niven Narain, the Co-Founder of Berg, said that it usually takes £1.7bn and 12 to 14 years to get a drug to market, however Berg expects this will be cut in half with the new AI system. Berg is to begin phase two trials of the cancer drug in January 2016.
Berg Health, a pharmaceutical startup, has developed a cancer drug in half the time expected by using a specialised form of artificial intelligence which takes samples from patients with the most aggressive strains of cancer and compares﻿ them to non-cancerous patients. The AI system looks at 14 trillion data points from a single patient tissue sample, and can highlight the differences between the corresponding biological profiles. Niven Narain, the Co-Founder of Berg, said that it usually takes £1.7bn and 12 to 14 years to get a drug to market, however Berg expects this will be cut in half with the new AI system. Berg is to begin phase two trials of the cancer drug in January 2016.